The estimated Net Worth of Alix Marduel is at least $5.92 million dollars as of 25 March 2008. Alix Marduel owns over 1,059,135 units of Corcept Therapeutics Inc stock worth over $5,918,755 and over the last 21 years Alix sold CORT stock worth over $0.
Alix has made over 4 trades of the Corcept Therapeutics Inc stock since 2007, according to the Form 4 filled with the SEC. Most recently Alix bought 1,059,135 units of CORT stock worth $2,933,804 on 25 March 2008.
The largest trade Alix's ever made was buying 1,500,000 units of Corcept Therapeutics Inc stock on 30 March 2007 worth over $1,500,000. On average, Alix trades about 835,253 units every 60 days since 2004. As of 25 March 2008 Alix still owns at least 166,491 units of Corcept Therapeutics Inc stock.
You can see the complete history of Alix Marduel stock trades at the bottom of the page.
Alix's mailing address filed with the SEC is ONE EMBARACDERO CENTER, SUITE 4050, , SAN FRANCISCO, CA, 94111.
Over the last 21 years, insiders at Corcept Therapeutics Inc have traded over $107,318,493 worth of Corcept Therapeutics Inc stock and bought 71,912,273 units worth $127,133,071 . The most active insiders traders include Patrick G Enright, Allen Andersson et Ventures, Llc Paperboy. On average, Corcept Therapeutics Inc executives and independent directors trade stock every 14 days with the average trade being worth of $8,010,233. The most recent stock trade was executed by William Guyer on 3 September 2024, trading 10,000 units of CORT stock currently worth $216,500.
leading the field in the discovery of drugs that modulate the effects of cortisol the adverse effects of excess cortisol have been corcept’s focus since the company’s inception. abnormal levels and release of cortisol play a role in a variety of metabolic, oncological, and psychiatric diseases, and we are currently studying a new generation of compounds that may mitigate the effects of excess cortisol. in addition to our work with mifepristone, we have developed over 300 proprietary molecules, advancing the most promising of these to the clinic to see if they can mitigate the effects of excess cortisol and the serious, sometimes life-threatening conditions that may result. all of these compounds competitively block the glucocorticoid receptor (gr), but not the progesterone receptor. scientific literature suggests that competitive gr antagonism may have a role in treating many conditions, including post-traumatic stress disorder, mild cognitive impairment, alzheimer’s disease, alcoholis
Corcept Therapeutics Inc executives and other stock owners filed with the SEC include: